Juno Therapeutics, Inc. (NASDAQ:JUNO) EVP Robert Azelby sold 6,666 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the sale, the executive vice president now directly owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Robert Azelby also recently made the following trade(s):

  • On Wednesday, September 13th, Robert Azelby sold 12,850 shares of Juno Therapeutics stock. The shares were sold at an average price of $44.95, for a total value of $577,607.50.
  • On Tuesday, August 29th, Robert Azelby sold 12,869 shares of Juno Therapeutics stock. The shares were sold at an average price of $39.95, for a total value of $514,116.55.

Shares of Juno Therapeutics, Inc. (NASDAQ JUNO) traded up $10.17 during trading on Friday, reaching $58.48. The company had a trading volume of 4,919,336 shares, compared to its average volume of 2,209,417.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million. During the same period last year, the business posted ($0.57) earnings per share. The company’s quarterly revenue was up 115.4% on a year-over-year basis. analysts expect that Juno Therapeutics, Inc. will post -3.53 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/03/insider-selling-juno-therapeutics-inc-juno-evp-sells-6666-shares-of-stock.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in JUNO. BlackRock Inc. boosted its position in shares of Juno Therapeutics by 31,399.7% during the first quarter. BlackRock Inc. now owns 4,183,793 shares of the biopharmaceutical company’s stock worth $92,838,000 after buying an additional 4,170,511 shares during the period. Redmile Group LLC purchased a new position in shares of Juno Therapeutics during the second quarter worth $66,344,000. Jennison Associates LLC boosted its position in shares of Juno Therapeutics by 162.0% during the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock worth $89,213,000 after buying an additional 1,229,622 shares during the period. Wasatch Advisors Inc. purchased a new position in shares of Juno Therapeutics during the second quarter worth $19,787,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Juno Therapeutics during the second quarter worth $9,693,000. Institutional investors and hedge funds own 67.18% of the company’s stock.

Several equities research analysts recently commented on JUNO shares. Vetr raised Juno Therapeutics from a “hold” rating to a “buy” rating and set a $28.85 price target for the company in a report on Monday, July 17th. Zacks Investment Research raised Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a report on Tuesday, July 11th. BidaskClub cut Juno Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 11th. Maxim Group reaffirmed a “buy” rating and issued a $56.00 price target (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $49.00 price target on shares of Juno Therapeutics in a report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $43.20.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.